Incyte Corp SEC Filings

Incyte Corporation reported an insider stock sale by its Executive Vice President and Chief Scientific Officer. On 12/10/2025, the officer sold 5,553 shares of common stock at $95.58 per share. On 12/11/2025, they sold another 255 shares at $94.94 per share. After these transactions, the reporting person directly beneficially owns 60,011 common shares. A footnote also identifies 59,858 additional shares of common stock issuable under previously reported restricted stock units that have not yet vested.

Incyte Corp’s Executive Vice President & Chief Medical Officer reported several stock transactions in early December 2025. On 12/01/2025, the insider sold 2,559 shares of common stock at $102.96 per share and had 100,327 shares beneficially owned afterward. That same day, 17,093 shares were withheld by the company at $102.04 per share to cover tax obligations tied to previously reported restricted stock units and performance shares.

On 12/02/2025, the insider sold an additional 20,105 shares at $102.51 per share, leaving 63,129 shares beneficially owned. According to the explanation, this total includes shares issuable under restricted stock units and earned performance shares that have not yet vested.

Incyte Corporation (INCY) reported insider stock transactions by its Principal Accounting Officer on a Form 4. The officer sold 169 shares of common stock on 11/21/2025 at $102 per share and 600 shares on 11/24/2025 at $103 per share. After these sales, the officer directly owned 23,573 shares of Incyte common stock.

The filing also notes that, including a July 15, 2025 grant, the officer holds an aggregate of 15,166 shares of common stock issuable from previously reported restricted stock units that have not yet vested. These transactions reflect personal trading activity by a company officer and ongoing equity-based compensation.

Incyte Corporation’s EVP & General Counsel filed a Form 4 reporting a small insider transaction. On 11/17/2025, the executive exercised an employee stock option to acquire 278 shares of common stock at $64.25 per share and on the same day sold 278 shares at $104.36 per share. After these transactions, the executive directly owned 26,569 shares of Incyte common stock and held 8,883 employee stock options. The filing also notes 25,913 shares of common stock underlying previously reported restricted stock units and earned performance units that are issuable but not yet vested.

Incyte Corporation (INCY) filed a Form 4 disclosing an insider sale. A director reported selling 187,500 shares of common stock on 11/10/2025 at a price of $105.46 per share. Following this transaction, the reporting person beneficially owns 329,646 shares, held directly.

The filing notes that this total includes 73,486 shares issuable from previously reported RSUs and earned performance shares that have not yet vested. No derivative securities were reported in Table II for this transaction. This is a routine insider ownership update and does not by itself indicate changes in company operations or strategy.

Incyte Corp (INCY): Form 4 insider activity. The company’s EVP & Chief Medical Officer reported option exercises and a same‑day sale on 11/05/2025.

The executive exercised options for 1,194 shares at $83.83, 2,995 shares at $95.76, and 1,044 shares at $95.76, then sold 5,233 shares at $102.20. Following these transactions, the executive beneficially owns 102,886 shares directly.

Footnotes note that 100,327 shares are issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. The exercised options were from grants that became exercisable per their original vesting schedules.

Incyte (INCY) insider activity: The company’s EVP & General Counsel reported a same‑day option exercise and sale on 11/04/2025. He exercised 598 employee stock options at $58.06 per share and sold 598 common shares at $101.36 per share.

Following these transactions, he directly owned 26,569 common shares. He also held 13,765 derivative securities (employee stock options) after the activity. In addition, the filing notes 25,913 shares of common stock are issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.

Incyte Corp (INCY) reported an insider transaction on Form 4. The company’s EVP, Head of Incyte Intl, sold 3,074 shares of common stock on 11/03/2025 at $94.02 per share.

Following the sale, the reporting person beneficially owned 29,241 shares directly. This figure includes 26,167 shares issuable pursuant to previously reported RSUs that have not vested.

Incyte reported stronger Q3 results, with total revenue of $1.366 billion, up from $1.138 billion a year ago. Net income rose to $424.2 million (diluted EPS $2.11) from $106.5 million ($0.54). Year to date, revenue reached $3.634 billion and net income was $987.4 million, a sharp improvement from a loss in the prior year.

Growth was broad-based: JAKAFI revenue was $791.1 million, OPZELURA $188.0 million, and new contributions included NIKTIMVO at $45.8 million and ZYNYZ at $22.7 million. Royalty revenue increased to $171.1 million, led by JAKAVI royalties of $125.6 million. Milestone and contract revenue was $45.0 million.

Operating expense trends were favorable. R&D for the quarter was $506.6 million versus $573.2 million, and cost of product revenues was $99.0 million. For the nine months, results also reflect a $242.3 million contract dispute settlement benefit tied to resolved JAKAFI royalties with Novartis and a 50% reduction in the ongoing U.S. JAKAFI royalty rate starting January 1, 2025. Cash and cash equivalents were $2.455 billion, with marketable securities of $474.8 million. Shares outstanding were 196,322,703 as of October 21, 2025.